The default
Routine vaccination protects the child and reduces transmission to infants, pregnant people, and immunocompromised neighbors.
Benefits outweigh harms Evidence review · Updated September 8, 2026
Vaccines have risks.
So do the diseases.
A clear, sourced guide to routine childhood vaccination in the United States—what the evidence shows, what it cannot prove, and how rare harms compare with the infections vaccines prevent.
Educational research, not individual medical advice. Scope: children from birth through age 18 in the U.S.
154Mestimated lives saved by vaccination globally since 1974
3.5–5Mdeaths prevented by immunization in a typical year
1.3 / 1Mconfirmed anaphylaxis cases per million vaccine doses in a large U.S. study
01 · The short answer
Should you vaccinate
your child?
For most children, yes—on the recommended pediatric schedule. That conclusion is not based on vaccines being perfectly safe. It is based on the expected benefits being much larger than the known risks.
Plain-language definitions Dotted-underlined terms—like anaphylaxisA sudden, severe allergic reaction that can affect breathing or blood pressure and requires immediate treatment.—can be hovered, tapped, or focused.
The exceptions
Severe allergy to a prior dose or component, severe immune suppression for some live vaccines, and prior intussusceptionA bowel blockage in which one part of the intestine slides inside another. It needs urgent medical evaluation and can require surgery. for rotavirus are examples requiring a different plan.
IndividualizeThe honest caveat
Recommendations are updated as evidence and disease patterns change. In 2026, the AAP and CDC schedules diverged in some areas; this report primarily follows the AAP pediatric schedule.
Current as of Aug. 202602 · Put risk in context
Compare outcomes,
not scary words.
Choose a topic. Every number shows its denominator, timeframe, and outcome—because “cases were reported” is not a risk estimate.
Brain inflammation from measles
1 in 1,000 casesAcute encephalitisInflammation of the brain, which can cause seizures, confusion, brain injury, or death. can cause permanent brain damage. Measles also kills about 1–3 in every 1,000 infected children.
vs.
Fever-related seizure after MMR
1 in 3,000–4,000 dosesA small, time-limited increased risk 6–14 days after vaccination. These febrile seizuresSeizures triggered by fever in young children. They are frightening but usually brief and do not cause lasting harm. generally have no long-term effects.
Context
CDC Pink Book, Measles chapterThese are not identical outcomes: encephalitisInflammation of the brain, which can cause seizures, confusion, brain injury, or death. is brain inflammation; a febrile seizureA seizure triggered by fever in a young child. It is frightening but usually brief and does not cause lasting harm. is a fever-triggered event. The comparison shows why vague language like “neurologic risk” can mislead.
03 · Before the vaccines
When prevention works,
the danger becomes invisible.
These are annual U.S. estimates from before routine vaccination—not forecasts of what would happen instantly if one child delayed a dose.
infections each year; 400–500 deaths and about 1,000 cases of brain inflammation among reported cases.
serious cases in young children and about 1,000 deaths each year.
people paralyzed each year before polio vaccines became available in the 1950s.
cases, 10,500–13,500 hospitalizations, and 100–150 deaths each year.
04 · Myth & claim checker
Type the claim.
Check the evidence.
The verdicts distinguish false claims from claims that contain a grain of truth but leave out decisive context.
CLAIM“Vaccines cause autism.”
Not supported by the evidenceHigh confidence+
“Vaccines cause autism.”
Large cohort studiesStudies that follow or compare defined groups of people over time to see how often outcomes occur. and meta-analysesStudies that statistically combine results from multiple studies to estimate the overall pattern of evidence. have found no association between vaccination and autism. A 2019 Danish study followed 657,461 children and found no increased autism risk after MMR—even among children considered at higher risk. Science rarely proves a universal negative, so the precise conclusion is that high-quality evidence does not support a causalShowing that one thing contributed to producing another—not merely that the two happened near each other. link.
CLAIM“The schedule gives children too many vaccines too soon.”
MisleadingModerate–high confidence+
“The schedule gives children too many vaccines too soon.”
Children encounter far more immune-stimulating material through ordinary life than through vaccines. Combination vaccines reduce injections, and recommended timing is chosen around when severe disease risk begins and when the immune response works well. Timing can change as evidence changes; it should be individualized for true contraindicationsSpecific reasons a medicine or vaccine should not be given because it could be harmful.—not stretched without a medical reason.
CLAIM“Natural infection is safer because it creates stronger immunity.”
Sometimes stronger; not saferHigh confidence+
“Natural infection is safer because it creates stronger immunity.”
CLAIM“Vaccine ingredients are toxic.”
Dose and formulation matterHigh confidence+
“Vaccine ingredients are toxic.”
An ingredient name alone does not establish danger. FDA reviews the amount, route, purpose, purity, and total product. Aluminum salts strengthen immune response in some vaccines. Thimerosal is absent from or avoidable in routine U.S. childhood formulations, and evidence has not supported a link with autism.
CLAIM“A VAERS report proves a vaccine caused the event.”
FalseHigh confidence+
“A VAERS report proves a vaccine caused the event.”
VAERSVaccine Adverse Event Reporting System: a U.S. early-warning database that accepts reports of health events after vaccination, whether or not the vaccine caused them. is an early-warning system that accepts reports after vaccination whether or not the vaccine caused the event. The reports are useful for detecting signals, but cannot by themselves calculate incidenceThe number of new cases occurring in a defined group during a defined period. or prove causation. Signals are investigated with medical review and comparison systems such as the Vaccine Safety DatalinkA U.S. research network linking vaccination records with medical records so suspected safety signals can be tested in large populations..
CLAIM“Diseases disappeared because sanitation improved—not vaccines.”
Sanitation helped; vaccines caused disease-specific collapsesHigh confidence+
“Diseases disappeared because sanitation improved—not vaccines.”
Cleaner water and better medical care reduced many harms, but the timing and specificity of declines track vaccine introduction. Before Hib vaccine, about 20,000 U.S. children developed serious Hib disease each year and about 1,000 died. After vaccine introduction, incidenceThe number of new cases occurring in a defined group during a defined period. fell dramatically while sanitation did not suddenly change for only Hib.
05 · How safety signals become evidence
After does not
automatically mean because.
Safety systems deliberately collect more than proven side effects. That sensitivity is useful—but it means the first report is the start of an investigation, not the conclusion.
1
→Event occurs
A health event happens after vaccination.
2
→Report / signal
VAERSVaccine Adverse Event Reporting System: a U.S. early-warning database that accepts reports of health events after vaccination, whether or not the vaccine caused them. or another system detects an unusual pattern.
3
→Test causality
Researchers verify diagnoses and compare observed with expected rates.
4
Act
Labels, guidance, dosing, or products can change if evidence supports a risk.
VAERSVaccine Adverse Event Reporting System: a U.S. early-warning database that accepts reports of health events after vaccination, whether or not the vaccine caused them. can answer: “Is there a pattern worth investigating?” It cannot answer by itself: “How often does this vaccine cause this condition?”
06 · The safety net
One database is not the system.
Clinical trials
Test immune response, effectiveness, common reactions, and serious events in defined populations. Trials cannot reliably find every one-in-a-million harm.
VAERSVaccine Adverse Event Reporting System: a U.S. early-warning database that accepts reports of health events after vaccination, whether or not the vaccine caused them.
Open, sensitive reporting from clinicians, manufacturers, patients, and families. Fast signal detection; limited causalShowing that one thing contributed to producing another—not merely that the two happened near each other. interpretation.
VSD, BEST & Sentinel
Large linked health-data systems compare rates, test signals, and evaluate safety in real-world populations.
Evidence panels
FDA, medical societies, and advisory groups assess benefits, risks, contraindications, and schedule changes.
07 · Known risks, plainly stated
The risks misinformation
should not be allowed to own.
RiskBest current estimateWhat changes clinically
AnaphylaxisA sudden, severe allergic reaction that can affect breathing or blood pressure and requires immediate treatment.About 1.3 per million doses across vaccines in one large U.S. studyScreen, observe when indicated, treat immediately, avoid repeat exposure to the culprit.
MMR febrile seizureA seizure triggered by fever in a young child. It is frightening but usually brief and does not cause lasting harm.About 1 per 3,000–4,000 children, 6–14 days after vaccinationDiscuss seizure history; separate MMR + varicella can avoid the additional first-dose MMRV risk.
Rotavirus intussusceptionA bowel blockage in which one part of the intestine slides inside another. It needs urgent medical evaluation and can require surgery.About 1 additional case per 20,000–100,000 vaccinated U.S. infantsDo not give after prior intussusceptionA bowel blockage in which one part of the intestine slides inside another. It needs urgent medical evaluation and can require surgery. or with SCIDSevere combined immunodeficiency: a group of rare disorders in which the immune system is profoundly weakened.; know early warning signs.
Live vaccines in severe immune suppressionRisk varies by condition and productSome live vaccines are contraindicatedNot recommended because a specific condition makes the risk unacceptably high.; use a specialist-guided plan.
08 · COVID-19 vaccines
The COVID vaccine:
what we know now.
More than five years of follow-up has made the safety picture clearer. The vaccines are not risk-free. The central established serious risk from mRNAMessenger RNA: short-lived genetic instructions that tell cells to make one harmless viral protein so the immune system can learn to recognize it. vaccines is rare heart inflammation, concentrated in adolescent and young adult males.
BOTTOM LINE FOR CHILDREN
Benefits vary more by age and health now than they did during the pandemic.
For 2026–2027, the AAP recommends an initial series for all children 6–23 months, or one dose if they already completed an initial series. It recommends additional dosing for moderately or severely immunocompromised children, one dose for other high-risk children ages 2–18, and offering one dose to any child ages 2–18 whose family desires protection. A child’s prior doses, health and household risk all matter. See S31 ↘
Hours to a few days
Pain at the injection site, tiredness, headache, chills, muscle aches, and fever. In very young children, irritability, sleepiness, and reduced appetite are common. These reactions usually resolve without lasting effects.
MyocarditisInflammation of the heart muscle. Symptoms can include chest pain, shortness of breath, or a fast or pounding heartbeat. / pericarditisInflammation of the thin sac surrounding the heart, often causing sharp chest pain.
Most often begins within one week. The highest observed risk is in males 12–24. Chest pain, shortness of breath, or palpitationsThe sensation that the heart is racing, pounding, fluttering, or skipping beats. after vaccination should be evaluated promptly.
AnaphylaxisA sudden, severe allergic reaction that can affect breathing or blood pressure and requires immediate treatment.
A severe allergic reaction can happen after any vaccine, usually within minutes to hours. Vaccination sites are prepared to treat it with epinephrineThe first-line emergency medicine for anaphylaxis; it rapidly improves breathing and blood pressure..
Infertility, Bell palsySudden temporary weakness or paralysis of the muscles on one side of the face., GBSGuillain-Barré syndrome: a rare disorder in which the immune system attacks peripheral nerves, causing weakness and sometimes paralysis., TTSThrombosis with thrombocytopenia syndrome: a rare combination of unusual blood clots and low platelets linked to some adenovirus-based COVID vaccines, not mRNA vaccines., heart attack
A 2024 National Academies review favored rejection of causalShowing that one thing contributed to producing another—not merely that the two happened near each other. links between Pfizer/Moderna vaccines and these outcomes. For many other proposed rare outcomes, evidence was still insufficient—not proof either way. S30
THE BEST CURRENT FDA ESTIMATE
Real but rareHeart inflammation after an mRNA dose
8cases per million doses
Ages 6 months–64 years overall, during days 1–7 after a 2023–2024-formula dose.
27cases per million doses
Males ages 12–24 during the same seven-day window—the highest-risk group.
These are unadjusted FDA estimates from insurance claims, not a prediction for every child or every formulation. Risk changes with sex, age, dose number, product, spacing, and prior infection. Source S21
VACCINE0.85 extra cases
of myocarditis or pericarditis per 100,000 vaccinated children over six months.
vs.
COVID-19 INFECTION2.24 extra cases
per 100,000 infected children over six months.
Nearly 14 million children in England, 2020–2022. The vaccine increase was short-term; infection-related risks were higher and lasted longer. These historical estimates may not perfectly match today’s variants, immunity, or formulations. S29
THE LONG-TERM QUESTION
What has—and has not—shown up?
Large safety systems have not found a broad pattern of delayed chronic illness in vaccinated children. Studies in young children found mostly mild-to-moderate reactions and no unexpected safety concerns; active surveillance after more than 726,000 doses in children 5–11 found no safety signal. S26 S27
Among people who actually developed vaccine-associated myocarditis, FDA says abnormal cardiac MRIA scan that uses magnets and radio waves to create detailed pictures of the heart muscle; it does not use radiation. findings were still common around five months, though often improved. What those findings predict years later is unknown. Long-term heart studies are still underway. S21 S24
mRNAMessenger RNA: short-lived genetic instructions that tell cells to make one harmless viral protein so the immune system can learn to recognize it. delivers temporary instructions in the cell’s outer compartment; it does not enter the nucleus where DNA is stored, and it is broken down. The vaccines are not gene therapyTreatment intended to add, remove, or change genetic material inside a person’s cells. mRNA vaccines do not do this..
Current population evidence has not shown COVID vaccination causing cancer, autoimmune diseaseA condition in which the immune system mistakenly attacks the body’s own cells or tissues., or a chronic syndrome resembling long COVIDSymptoms or health problems that continue or appear after the acute COVID-19 infection has passed.. That is strong reassurance, not proof that an ultra-rare or decades-later effect is mathematically impossible.
What vaccination can still prevent
Severe acute disease: Updated vaccines provide additional, time-limited protection against emergency visits and hospitalization, though protection against any infection is less reliable and wanes.
MIS-CA rare, serious inflammatory condition that can affect a child’s heart and other organs after COVID-19 infection.: Vaccination reduces the risk of this rare multi-organ inflammatory complication after infection.
Long COVIDSymptoms or health problems that continue or appear after the acute COVID-19 infection has passed.: Systematic reviews find vaccination before infection reduces the risk, though study estimates vary and vaccination cannot prevent every case. S28
The FDA selected a monovalent JN.1-lineage XFG composition for U.S. 2026–2027 COVID-19 vaccines. Formula selection does not itself establish the age-specific benefit of vaccination. S32
6–23 monthsAAP recommends vaccination for all
Young children have higher hospitalization risk and often lack prior immune protection.
2–18 years, higher riskAAP recommends a dose
Includes certain medical conditions, immune compromise, congregate living, never vaccinated, or a high-risk household contact.
2–18 years, otherwise healthyOffer if the family desires protection
The expected personal benefit is smaller than for infants or high-risk children, so values and current exposure matter more.
09 · Method & limits
How this report
decides what is true.
Designed to be useful to a skeptical reader—not to demand trust in a logo or institution.
Prefer stronger designs
Systematic reviews, large cohort studiesStudies that follow or compare defined groups of people over time to see how often outcomes occur., active surveillanceA safety system that proactively checks health records or contacts people, rather than waiting for voluntary reports., and replicated findings outweigh anecdotes and raw report counts.
Separate signal from cause
Temporality is necessary for causation, but not sufficient. We look for excess risk, consistency, plausible timing, and alternative explanations.
Use absolute risk
“Doubles the risk” can mean 1 in a million became 2 in a million. We show denominators and time windows where available.
State uncertainty
“No evidence of a link” is not the same sentence as “mathematically impossible.” Confidence reflects the size and consistency of the evidence.
Scope limits
This is a narrative evidence review, not a systematic review or clinical guideline. It focuses on routine U.S. childhood vaccination; product formulations and recommendations can change. COVID-19 recommendations are especially time-sensitive. Source access date: September 8, 2026.
10 · Adversarial review
Where could this site
be wrong or misleading?
Institutional sources can change
Public-health agencies are authoritative for surveillance data, but policy pages can shift with leadership. We pair them with peer-reviewed studies and medical-society guidance.
Pre-vaccine history is not today’s counterfactual
Old disease burden shows what the pathogen can do, not exactly what would happen next year under any single change in coverage.
Rare harms are hard to measure
Trials miss very rare events; observational systems can have confounding and misclassification. Wide ranges are more honest than false precision.
“Vaccines” are not one product
Risk varies by vaccine, age, dose, formulation, and medical history. A conclusion about MMR does not automatically transfer to rotavirus or COVID-19 vaccine.
11 · Frequently asked questions
Questions parents
actually ask.
Concise answers for humans and search engines, with clinical exceptions kept visible.
For most children, the evidence supports receiving routine vaccines on the pediatric schedule: the expected protection from serious disease is much greater than the risk of serious vaccine harm. The answer can differ for a child with a severe allergy to a prior dose, certain immune disorders, a history of intussusceptionA bowel blockage in which one part of the intestine slides inside another. It needs urgent medical evaluation and can require surgery. before rotavirus vaccine, or other specific precautions. Review the current schedule and your child’s history with a pediatric clinician.
12 · Sources
Read the evidence,
not just our summary.
Primary public-health data and peer-reviewed research. Links go to the exact page or paper used.
S1Hviid et al. (2019), MMR vaccination and autism; nationwide cohort of 657,461 children↗S2Taylor et al. (2014), vaccines and autism meta-analysis↗S3CDC: Clinical overview of measles and complication rates↗S4CDC Pink Book: Measles vaccine safety and disease epidemiology↗S5CDC: Preventing and managing vaccine adverse reactions↗S6CDC: About the Vaccine Adverse Event Reporting System↗S7FDA: VAERS as an early-warning system↗S8FDA: Vaccine development, approval, and safety monitoring↗S9FDA: Common ingredients in approved vaccines↗S10FDA: Thimerosal and vaccines↗S11CDC: Rotavirus vaccination and intussusception risk↗S12CDC: Hib vaccine history and pre-vaccine burden↗S13CDC: Impact of the U.S. chickenpox vaccination program↗S14American Academy of Pediatrics: 2026 childhood immunization schedule↗S15WHO: Vaccines and immunization; global impact estimate↗S16WHO-led modeling: 154 million lives saved by immunization since 1974↗S17McNeil et al. (2016), anaphylaxis after vaccination across 25.1 million doses↗S18Andersson et al. (2025), aluminum-adsorbed vaccines and 50 chronic disorders↗S19CDC: Contraindications and precautions for vaccination↗S20WHO: How vaccine safety is monitored↗S21FDA (2025): Updated mRNA COVID-19 vaccine warning for myocarditis and pericarditis↗S22American Academy of Pediatrics: 2025–2026 COVID-19 vaccine recommendations for children↗S23American Academy of Pediatrics (2026): COVID-19 vaccine evidence summary for parents↗S24Jain et al. (2024): Longitudinal outcomes after COVID vaccine-associated myocarditis↗S25National Academies (2024): Independent review of possible COVID-19 vaccine harms↗S26Hause et al. (2022): mRNA COVID-19 vaccine safety in children 6 months–5 years↗S27Hause et al. (2022): U.S. safety surveillance in children 5–11 years↗S28Català et al. (2024): Systematic review of vaccination and long COVID risk↗S29Sampri et al. (2025): Vascular and inflammatory outcomes after infection versus vaccination in nearly 14 million children↗S30National Academies (2024): Summary of conclusions on myocarditis, infertility, Bell palsy, GBS, and clotting↗S31American Academy of Pediatrics: 2026–2027 pediatric COVID-19 vaccine recommendations↗S32FDA: 2026–2027 COVID-19 vaccine formula (monovalent JN.1-lineage XFG)↗